CVS Health (CVS)
(Delayed Data from NYSE)
$58.75 USD
+1.01 (1.75%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $58.89 +0.14 (0.24%) 7:58 PM ET
5-Strong Sell of 5 5
A Value D Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$58.75 USD
+1.01 (1.75%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $58.89 +0.14 (0.24%) 7:58 PM ET
5-Strong Sell of 5 5
A Value D Growth F Momentum C VGM
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
Here is What to Know Beyond Why CVS Health Corporation (CVS) is a Trending Stock
by Zacks Equity Research
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
New Strong Sell Stocks for August 15th
by Zacks Equity Research
ARCO, CNMD and CVS have been added to the Zacks Rank #5 (Strong Sell) List on August 15, 2024.
Wall Street Bulls Look Optimistic About CVS Health (CVS): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in CVS Health (CVS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
New Strong Sell Stocks for August 13th
by Zacks Equity Research
ADM, ACLS and CVS have been added to the Zacks Rank #5 (Strong Sell) List on August 13, 2024.
The Zacks Analyst Blog CVS Health, Walgreens and Herbalife
by Zacks Equity Research
CVS Health, Walgreens and Herbalife are included in this Analyst Blog.
What is the Right Approach for CVS Health (CVS) Post Q2 Results?
by Urmimala Biswas
The near-term challenges for CVS Health (CVS) are no doubt worrisome. Yet, the company remains focused on its strategic moves, utilizing integrated healthcare models and technological advancements.
Compared to Estimates, CVS Health (CVS) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for CVS Health (CVS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CVS Health (CVS) Beats Q2 Earnings, Narrows '24 EPS Outlook
by Zacks Equity Research
CVS Health (CVS) delivers a year-over-year improvement in revenues, driven by growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments.
CVS Health (CVS) Beats Q2 Earnings Estimates
by Zacks Equity Research
CVS Health (CVS) delivered earnings and revenue surprises of 5.17% and 0.35%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
CVS Health (CVS) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for CVS Health (CVS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
CVS Health (CVS) Stock Moves -0.5%: What You Should Know
by Zacks Equity Research
In the most recent trading session, CVS Health (CVS) closed at $60.03, indicating a -0.5% shift from the previous trading day.
Herbalife Ltd (HLF) Tops Q2 Earnings Estimates
by Zacks Equity Research
Herbalife Ltd (HLF) delivered earnings and revenue surprises of 25.58% and 3.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate CVS Health (CVS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CVS Health (CVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CVS Health (CVS) Stock Pre-Q2 Earnings: To Buy or Not to Buy?
by Urmimala Biswas
CVS Health (CVS) is grappling with a sudden increase in Medicare Advantage members' utilization trend. The Medicaid business, too, is expected to have experienced medical cost pressure in the second quarter.
Wall Street Analysts Think CVS Health (CVS) Is a Good Investment: Is It?
by Zacks Equity Research
The average brokerage recommendation (ABR) for CVS Health (CVS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
CVS Health (CVS) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
The latest trading day saw CVS Health (CVS) settling at $58.65, representing a +0.19% change from its previous close.
CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FVD
CVS Health (CVS) Stock Moves -0.57%: What You Should Know
by Zacks Equity Research
The latest trading day saw CVS Health (CVS) settling at $59.57, representing a -0.57% change from its previous close.
CVS Health (CVS) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
The average brokerage recommendation (ABR) for CVS Health (CVS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
CVS Health (CVS) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, CVS Health (CVS) stood at $57.53, denoting a -0.16% change from the preceding trading day.
CVS Health (CVS) Falls 24% in 3 Months: Should You Buy the Dip?
by Urmimala Biswas
While CVS Health (CVS) has been grappling with the pharmacy reimbursement pressure, a turnaround might be in the cards given its several strategic initiatives.
CVS Health (CVS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $59.06, marking a +1.2% move from the previous day.
UnitedHealth (UNH) Stock Drops 8% YTD: Should You Hold or Fold?
by Kaibalya Pravo Dey
As commercial business improves within the industry, UnitedHealth (UNH), with its diverse portfolio of offerings, is well-positioned to capitalize on the rising demand.
Is It Worth Investing in CVS Health (CVS) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), CVS Health (CVS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?